studies

breast cancer (BC), IGF-1R inhibitors vs. exemestane plus ridaforolimus, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsMK-8669-064, 2017 1.18 [0.81; 1.72] 1.18[0.81; 1.72]MK-8669-064, 201710%80NAnot evaluable objective responses (ORR)detailed resultsMK-8669-064, 2017 0.53 [0.17; 1.63] 0.53[0.17; 1.63]MK-8669-064, 201710%80NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-07-01 06:39 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 1427,1441,1428